多发性硬化症疾病修饰疗法的演变:针对药剂师的更新
Alexandra Edinger1, Mitra Habibi2
1Northwestern Medicine Specialty Pharmacy, Chicago, IL, USA.
概括
多发性硬化症 (MS) 的疾病修饰疗法 (DMT) 已经显著发展,提供了更好的疗效和管理. 然而,不断上升的成本和限制仍然是管理这种渐进的神经疾病的关键挑战.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 多发性硬化症 (MS) 是一种进展性,免疫媒介的神经疾病,影响年轻成年人.
- 多发性硬化会导致显著的运动和认知障碍.
- 这种疾病通常影响20至40岁的个体.
研究的目的:
- 讨论多发性硬化症 (MS) 疾病修饰疗法 (DMT) 的演变.
- 审查DMT的指示,作用机制,疗效,怀孕方面的考虑和成本.
- 要突出不断变化的治疗环境和药剂师的作用.
主要方法:
- 关于多发性硬化症疾病修饰疗法的文献综述.
- 分析历史和当前的治疗策略.
- 讨论治疗方面的进步和挑战.
主要成果:
- 自1993年以来,DMT开发取得了显著进展,新的类提供了更高的疗效和更简单的管理.
- 现在,DMT为MS患者提供了更好的治疗选择.
- 缺点包括增加的成本和DMT的表单限制.
结论:
- 在过去的二十年中,多发性硬化症治疗的格局发生了变化.
- 较新的DMT类为增强患者管理提供了机会.
- 药剂师对于管理多发性硬化症患者及其不断发展的治疗方法至关重要.
相关概念视频
Drug Therapy
60
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
60
Inflammatory Bowel Disease IV: Pharmacological Management
145
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
145
Drug Administration and Therapy Phases: Overview
504
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
504
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
186
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
186
Myasthenia Gravis: Overview and Treatment
1.6K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.6K
Psychosis: Goals of Pharmacotherapy
158
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
158


